Peak Bio, Inc. Research and Development Expense
Peak Bio, Inc. reported Research and Development Expense of $112.21 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-11-12
- Peak Bio, Inc. research and development expense for the quarter ending 2024-09-30 was $112.21K, a 79.71% decline year-over-year.
- Peak Bio, Inc. research and development expense for the quarter ending 2024-06-30 was $108.64K, a 70.73% decline year-over-year.
- Peak Bio, Inc. research and development expense for the quarter ending 2024-03-31 was $70.27K, a 90.15% decline year-over-year.
- Peak Bio, Inc. research and development expense for the quarter ending 2023-12-31 was -$9.86K, a 102.05% decline year-over-year.
- Peak Bio, Inc. research and development expense for fiscal 2023 was $1.63M, a 58.53% decline from fiscal 2022.
- Peak Bio, Inc. research and development expense for fiscal 2022 was $3.92M, a 44.92% decline from fiscal 2021.
- Peak Bio, Inc. research and development expense for fiscal 2021 was $7.12M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $112.21K 10-Q · filed 2024-11-12 | $220.85K derived: sum of 2 quarters · filed 2024-11-12 | $291.12K 10-Q · filed 2024-11-12 | $281.27K derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $108.64K 10-Q · filed 2024-08-23 | $178.91K 10-Q · filed 2024-08-23 | $169.05K derived: sum of 3 quarters · filed 2024-08-23 | $722.04K derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | $70.27K 10-Q · filed 2024-08-23 | $60.41K derived: sum of 2 quarters · filed 2024-08-23 | $613.40K derived: sum of 3 quarters · filed 2024-11-12 | $984.55K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | -$9.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-06 | $543.13K derived: sum of 2 quarters · filed 2024-11-12 | $914.28K derived: sum of 3 quarters · filed 2024-11-12 | $1.63M 10-K · filed 2024-08-06 |
| 2023-09-30 | $552.99K 10-Q · filed 2024-11-12 | $924.14K derived: sum of 2 quarters · filed 2024-11-12 | $1.64M 10-Q · filed 2024-11-12 | $2.12M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $371.15K 10-Q · filed 2024-08-23 | $1.08M 10-Q · filed 2024-08-23 | $1.57M derived: sum of 3 quarters · filed 2024-08-23 | $2.43M derived: sum of 4 quarters · filed 2024-08-23 |
| 2023-03-31 | $713.11K 10-Q · filed 2024-08-23 | $1.19M derived: sum of 2 quarters · filed 2024-08-23 | $2.06M derived: sum of 3 quarters · filed 2024-08-23 | $3.23M derived: sum of 4 quarters · filed 2024-08-23 |
| 2022-12-31 | $481.11K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-06 | $1.35M derived: sum of 2 quarters · filed 2024-08-06 | $2.52M derived: sum of 3 quarters · filed 2024-08-06 | $3.92M 10-K · filed 2024-08-06 |
| 2022-09-30 | $868.41K 10-Q · filed 2024-06-25 | $2.04M derived: sum of 2 quarters · filed 2024-06-25 | $3.44M 10-Q · filed 2024-06-25 | |
| 2022-06-30 | $1.17M 10-Q · filed 2023-08-18 | $2.57M 10-Q · filed 2023-08-18 | ||
| 2022-03-31 | $1.41M 10-Q · filed 2023-07-12 | |||
| 2021-12-31 | $7.12M 10-K · filed 2023-06-29 |